The caffeine test measures the activity of cytochrome P450 (CYP1A2) which is a major enzyme involved in the activation of flutamide. The usefulness of this test in predicting flutamide-induced hepatic injury in patients with prostate cancer was examined. The subjects were: (1) five patients whose aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level rose to 100 IU/l or higher following the start of flutamide (moderately injured group); (2) four patients whose AST and ALT levels were higher than normal but less than 100 IU/l (mildly injured group); and (3) two patients whose hepatic function remained normal (normal group). The subjects were each given canned coffee to drink. Urinary caffeine (137X), paraxanthine (17X) and 1, 7-dimethyluric acid (17U) levels were measured 4 -5 h later. The metabolite ratio, (17U þ 17X)/137X, was calculated to serve as an indicator of CYP1A2 activity. The metabolite ratio for the moderately injured group (3.98 AE 1.56) and the mildly injured group (5.55 AE 1.42) were lower than that for the normal group (9.56). The results suggest that a decrease in CYP1A2 activity is involved in the onset of flutamide-induced hepatic injury, and that the caffeine test seems to provide a useful means of its prediction.
Introduction
Flutamide, a non-steroidal antiandrogen, has been widely used in endocrine therapy for prostate cancer, and its effectiveness has been demonstrated, 1 however, hepatic injury is one of the adverse reactions to this drug in Japan. 2 -4 It is suggested that the degradation of flutamide by cytochrome P450 (CYP1A2) is involved in this adverse reaction, 5 although details remain obscure. OH-flutamide, an active metabolite of flutamide, acts as a testosterone antagonist and exerts antiandrogenic action and this pathway of flutamide metabolism primarily involves CYP1A2. 6, 7 Of the currently available methods of evaluating the activity of enzymes involved in drug metabolism in vivo, the caffeine test has been used as a non-invasive means of evaluating CYP1A2 activity. 8, 9 The present investigation was conducted to examine the relationship between CYP1A2 activity, measured by the caffeine test, and liver enzyme markers in patients who had developed flutamide-induced hepatic injury. We thus evaluated the usefulness of the caffeine test as a means of predicting the onset of this adverse reaction following flutamide.
Materials and methods
The subjects of this study were 11 patients who commenced flutamide for prostate cancer in the Department of Urology, Nara Medical University and its affiliated hospitals after May 1995. There were five patients whose aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels rose to 100 IU/l or higher following commencement of flutamide (moderately injured group), four patients whose AST and/or ALT levels were higher than normal but less than 100 IU/l following commencement of flutamide (mildly injured group) and two patients whose hepatic function remained normal (normal group). All of these patients had been rated as having no hepatic function abnormalities immediately before this study. Since smoking can induce CYP1A2, smokers were excluded from the study. Patients with renal dysfunction were also excluded.
All patients were informed of (1) the purpose and method of the study, (2) the safety of the study, (3) freedom to refuse to participate in the study, (4) freedom to withdraw consent at any time even if it has already been given, and (5) relevant matters concerning personal rights. Written consent was obtained from each patient.
The caffeine test was performed using a modification of the method reported by Nakajima et al 10 and Butler et al. 11 Patients refrained from consuming methylxanthincontaining foods, beverages and drugs from the previous day until finishing the test. On the day of the test, early in the morning before breakfast, each patient was given canned coffee (190 g; KIRIN Beverage Co. Ltd.) containing about 150 mg caffeine, to drink. A 1-h urine sample was collected between 4 and 5 h after coffee intake. The urine samples were frozen immediately after collection and stored at below 7 80 C until analyses. Urinary levels of caffeine (137X) and its metabolites 1,7-dimethylxanthine (17X) and 1,7-dimethyluric acid (17U) were measured by high-performance liquid chromatography (HPLC). 10 -12 The urinary metabolite ratio, (17X þ 17U)/137X, was calculated to serve as an indicator of CYP1A2 activity. 10, 11 The statistical significance of any differences was tested using Tukey's test.
Results
The caffeine test was conducted on 11 patients who had received treatment with flutamide.
Urine samples collected 4 -5 h after drinking canned coffee were subjected to HPLC to quantify caffeine and its metabolites. Figure 1 shows a representative chart thus obtained. The metabolite ratio was calculated to serve as a measure of CYP1A2 activity. 
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The urinary metabolite ratio, (17X þ 17U)/137X, was 3.98 AE 1.56 in the moderately injured group and 5.55 AE 1.42 in the mildly injured group. The ratio was 9.56 in the normal group, which was higher than that for patients who had developed flutamide-induced hepatic injury ( Figure 2 ). The peak AST and ALT levels recorded during flutamide treatment correlated with the urinary metabolite ratio (r ¼ 7 0.67 and 7 0.74, respectively), as shown in Figures 3 and 4 . The onset of hepatic injury showed no correlation with patient age, height or body weight (Table 1) .
Discussion
Flutamide, a non-steroidal antiandrogen, has been widely accepted as an effective therapy for prostate cancer. 1 Particularly close attention has been paid to maximum androgen blockade (MAB) that uses antiandrogen in combination with LHRH (luteinizing hormone releasing hormone) analogue. We have previously reported the usefulness of MAB involving flutamide. 13 However, the onset of severe hepatic injury has been reported as an adverse reaction to this therapy in Japan, although diarrhoea could be seen as the main adverse reaction in Europe and the USA. 2 -4 In our previous randomized controlled trial (RCT) designed to compare the usefulness of flutamide and chlormadinone acetate (CMA), a steroidal antiandrogen, in MAB, the incidence of hepatic dysfunction was shown to be significantly higher in the flutamide group. It has also been suggested that periodical monitoring is essential during flutamide treatment even when the pre-treatment liver function is normal. 14 As a result of these findings, we have investigated the incidence of flutamide-induced hepatic injury, and found abnormal AST or ALT levels in 116 (35.0%) out of 331 patients, including two (0.6%) with severe AST or ALT abnormalities. 15 The mechanism of this adverse event has not yet been fully elucidated, although it has suggested the involvement of drug metabolism by cytochrome P-450. 5 Flutamide is metabolized in vivo to give an active metabolite, OH-flutamide, which acts as a testosterone antagonist and exerts antiandrogenic activity. Experiments using Figure 3 The relationship of aspartate aminotransferase and urinary molar ratio of (17U þ 17X)/137X 4 -5 h after coffee intake in patients treated with flutamide. The highest value during administration period of flutamide. b The urinary molar ratio of (17U þ 17X)/137X 4 -5 h after coffee intake. Figure 4 The relationship of alanine aminotransferase and urinary molar ratio of (17U þ 17X)/137X 4 -5 h after coffee intake in patients treated with flutamide.
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human liver microsomes have demonstrated that this pathway of flutamide metabolism primarily involves CYP1A2. 6, 7 Serum concentration of OH-flutamide in patients with hepatic dysfunction were lower than in patients who maintained normal liver function, suggesting that the activation of flutamide into OH-flutamide was compromised in these patients. 16 It is known that CYP1A2 is induced by smoking, and that the risk for developing flutamide-induced hepatic injury is lower in smokers. 17 These results suggest that one factor responsible for the flutamide-induced hepatic injury is reduced CYP1A2 activity. A variety of methods have been reported for evaluation of the activity of enzymes involved in drug metabolism in vivo. The caffeine test, a non-invasive method, has been used to evaluate CYP1A2 activity. 8, 9 To examine the relationship between onset of hepatic dysfunction and CYP1A2 activity and to explore a method of predicting the flutamide-induced hepatic injury, we conducted the caffeine test in 11 patients treated with flutamide.
The urinary caffeine metabolite ratio, an indicator of CYP1A2 activity, was significantly lower in patients who had developed flutamide-induced hepatic injury compared to patients whose hepatic function had remained normal after the same therapy. This result suggests that a decrease in CYP1A2 activity is involved in the onset of flutamide-induced hepatic injury. It seems possible that in patients who develop hepatic injury, a decrease in CYP1A2 activity reduces the metabolization of flutamide into OH-flutamide and increases the formation of other metabolites which may damage hepatocytes. The results of a basic study conducted by Fau et al suggested the possibility that electrophilic metabolites might be responsible for hepatic dysfunction associated with flutamide. 5 CYP1A2, which was found to correlate with the flutamide-induced hepatic injury in the present study, was previously reported to show genetic polymorphism. Nakajima et al reported, on the basis of caffeine test, that CYP1A2 activity was low in 14.1% of Japanese. 10 Mutations at several points in the gene encoding CYP1A2 have been reported. If the relationship between these mutations, CYP1A2 activity and flutamide-induced hepatic injury can be established, it may be possible in the future to identify, by means of genetic diagnosis, patients at high risk of developing hepatic injury. However, it has also been shown that the activity of this enzyme can vary greatly not only as a result of genetic mutations but also due to the influence of extrinsic factors (such as smoking, diet, and drugs). It seems therefore more useful to develop an evaluation of enzyme activity that will allow for the identification of individuals with congenital or acquired inadequacy of CYP1A2 activity.
Usually, this evaluation uses information about metabolization activity by analyzing pharmacodynamic parameters (half-life and clearance). To this end, frequent blood and urine sampling is needed, both stress-inducing in the patient and procedurally labour-intensive. The caffeine test, on the other hand, allows evaluation of the metabolic capacity of the liver using only one urine sample, collected after consumption of coffee, and thus can reduce stress to the patient and minimize evaluation procedures. Considering these advantages, evaluation of CYP1A2 activity using the caffeine test seems to provide a useful means of predicting an individual's risk of developing severe flutamide-induced hepatic injury. Furthermore, the caffeine test is suitable for evaluation of the drug-degrading capacity of the liver because: (1) caffeine is contained in beverages widely consumed by most races and nations; (2) caffeine has little toxicity manifested through enzyme induction, and little pharmacologic action; and (3) caffeine is absorbed rapidly and is mostly degraded by the liver.
The results of this study suggest that CYP1A2 is involved in the onset of flutamide-induced hepatic injury. Care is therefore needed when administering flutamide to patients with low CYP1A2 activity. The results also indicate that the caffeine test is useful for evaluation of CYP1A2 activity, and that this test will allow us to identify individuals who are at increased risk of developing this adverse reaction.
